These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 16964833

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T, Ryan EJ, Norris S, Hegarty JE, O'Farrelly C.
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Granulocyte colony stimulating factor in HCV genotype-1 patients who develop Peg-IFN-alpha2b related severe neutropenia: a preliminary report on treatment, safety and efficacy.
    Koskinas J, Zacharakis G, Sidiropoulos J, Elefsiniotis J, Savvas S, Kotsiou S, Kountouras D, Schina M, Kostopoulos P, Archimandritis A.
    J Med Virol; 2009 May; 81(5):848-52. PubMed ID: 19319942
    [Abstract] [Full Text] [Related]

  • 6. Bone marrow suppression or active proliferation? An analysis of neutropenia after pegylated interferon treatment of patients with chronic hepatitis C.
    Liu YL, Du XF, Chen XY, Ma LN, Guo DD, Lu JF, Cao ZH, Zhang YH.
    Scand J Infect Dis; 2013 Dec; 45(12):939-43. PubMed ID: 24090457
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Haematologic adverse effects of treatment of chronic viral hepatitis B and C].
    Porubcin S, Schréter I, Kristian P, Pellová A.
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):74-8. PubMed ID: 18756437
    [Abstract] [Full Text] [Related]

  • 10. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients.
    Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N.
    Cytokines Cell Mol Ther; 2000 Sep; 6(3):149-54. PubMed ID: 11140884
    [Abstract] [Full Text] [Related]

  • 11. The impact of haematopoietic growth factors on the management and efficacy of antiviral treatment in patients with hepatitis C virus.
    Lebray P, Nalpas B, Vallet-Pichard A, Broissand C, Sobesky R, Serpaggi J, Fontaine H, Pol S.
    Antivir Ther; 2005 Sep; 10(6):769-76. PubMed ID: 16218177
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Granulocyte colony-stimulating factor for hepatitis C therapy-associated neutropenia: systematic review and economic evaluation.
    Tandon P, Doucette K, Fassbender K, Vandermeer B, Durec T, Dryden DM.
    J Viral Hepat; 2011 Jul; 18(7):e381-93. PubMed ID: 21692951
    [Abstract] [Full Text] [Related]

  • 14. A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection.
    Saleh MI, Hindi NN.
    Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):953-963. PubMed ID: 29872876
    [Abstract] [Full Text] [Related]

  • 15. Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.
    Iacobellis A, Cozzolongo R, Minerva N, Valvano MR, Niro GA, Fontana R, Palmieri O, Ippolito A, Andriulli A.
    Dig Liver Dis; 2014 Jul; 46(7):621-4. PubMed ID: 24675038
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment induced leucopenia in hepatitis C and Role of G-CSF in its management.
    Shafi MS, Sheikh NI, Rizvi F, Afzal M, Manzoor S.
    J Coll Physicians Surg Pak; 2009 Jun; 19(6):346-9. PubMed ID: 19486571
    [Abstract] [Full Text] [Related]

  • 19. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN.
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [Abstract] [Full Text] [Related]

  • 20. A phase II dose finding study of darbepoetin alpha and filgrastim for the management of anaemia and neutropenia in chronic hepatitis C treatment.
    Younossi ZM, Nader FH, Bai C, Sjogren R, Ong JP, Collantes R, Sjogren M, Farmer D, Ramsey L, Terra K, Gujral H, Gurung C, Srishord M, Fang Y.
    J Viral Hepat; 2008 May; 15(5):370-8. PubMed ID: 18194172
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.